Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

Xiao Wei,Fangjun Chen,Kai Xin,Qin Wang,Lixia Yu,Baorui Liu,Qin Liu
DOI: https://doi.org/10.1016/j.tranon.2019.02.008
IF: 4.803
2019-01-01
Translational Oncology
Abstract:Cancer vaccines, including peptide-based vaccines, have been considered a key tool of effective and protective cancer immunotherapy because of their capacity to provide long-term clinical benefit for tumors. Among a large number of explorations of peptide antigen-based vaccines, cancer-testis antigens (CTAs), which are activated in cancers but silenced in normal tissues (except testis tissue), are considered as ideal targets. Currently, personalized treatment for cancer has become a trend due to its superior clinical efficacy. Thus, we envisage rational selection of CTA peptides to design “personalized” CTA peptide vaccines. This review summarizes the advances in CTA peptide vaccine research and discusses the feasibility of establishing “personalized” CTA peptide vaccines.
What problem does this paper attempt to address?